Cancer immunotherapies by design, and in development.

Our efforts are targeting various cancer indications using our drug candidates either in monotherapy or in combination with additional drugs.

Our clinical team is currently investigating Inupadenant, an A2A receptor antagonist, as a treatment for solid tumors in monotherapy, combination with pembrolizumab and combination with chemotherapy, as well as advancing EOS-448, our ADCC-enabled anti-TIGIT antibody antagonist in Phase 1 trials, in patients with cancer.

“At iTeos, we specialize in targeted immunotherapies for people living with cancer.”

— Michel Detheux, Chief Executive Officer
two women hugging

Trial NCT05117177 (View at ClinicalTrials.gov)

This trial evaluates the safety, tolerability, pharmacokinetics, and food effect of Inupadenant in patients with advanced solid tumors. The purpose of this trial is to assess the safety of the drug, determine the maximum tolerated dose and recommended Phase 2 dose, and investigate the effect of food on the patient’s exposure to the drug.

Trial NCT03873883 (View at ClinicalTrials.gov)

This trial evaluates Inupadenant as a single agent therapy in patients with advanced solid tumors. It also evaluates Inupadenant in combination with Keytruda® and in combination with chemotherapy in specific indications. The purpose of this trial is to assess the safety of the drug alone and in combination, measure the amount of drug in the body after dosing, measure the effects of the drug on the body, and investigate the effect of the drug on the tumor.

Trial NCT05060432 (View at ClinicalTrials.gov)

This trial evaluates EOS-448 in combination with pembrolizumab, and also in combination with Inupadenant, in patients with advanced solid tumors. The purpose of this trial is to assess the safety and tolerability of EOS-448 when used in combination with each of these drugs, to determine the recommended Phase 2 dose, and to further explore the anti-tumor activity of each combination.

Trial NCT03739710 (View at ClinicalTrials.gov)

This trial evaluates the clinical activity of EOS-448 in combination with dostarlimab in patients with relapsed/refractory advanced non-small cell lung cancer. The purpose of this trial is to assess the drug’s safety, tolerability, and anti-tumor activity compared to other treatments.

Trial NCT04335253 (View at ClinicalTrials.gov)

This trial evaluates EOS-448 as a single agent therapy in patients with advanced solid tumors. The purpose of this trial is to evaluate the safety of the drug, measure the amount of drug in the body after dosing, measure the effects of the drug on the body, and evaluate the effect of the drug on the tumor.

Latest press releases

See all press releases